Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US-2023174645-A1 · Jun 8, 2023 · US
Composition and method for the diagnosis and treatment of iron-related disorders
US12098192B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12098192-B2 |
| Application number | US-202418638307-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 17, 2024 |
| Priority date | Dec 14, 2011 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising an anti-Repulsive Guidance Molecule c (RGMc) antibody that comprises: (i) a variable heavy chain region comprising a complementary determining region (CDR)1 with the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 with the amino acid sequence set forth in SEQ ID NO: 18, a CDR3 with the amino acid sequence set forth in SEQ ID NO: 19, and a variable light chain region comprising a CDR1 with the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 with the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 with the amino acid sequence set forth in SEQ ID NO:22; and (ii) a human IgG1 constant domain. 2. The composition of claim 1 , wherein the antibody is affinity matured. 3. The composition of claim 1 , wherein the variable light chain region has the amino acid sequence set forth in SEQ ID NO: 6. 4. The composition of claim 1 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO: 5 with up to one amino acid difference in a framework region. 5. The composition of claim 3 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO: 5 with up to one amino acid difference in a framework region. 6. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier. 7. The composition of claim 1 , wherein the composition is in a lyophilized form. 8. The composition of claim 1 , wherein the composition is in a solution form. 9. The composition of claim 5 , wherein the composition is in a lyophilized form. 10. The composition of claim 5 , wherein the composition is in a solution form. 11. A composition comprising an anti-Repulsive Guidance Molecule c (RGMc) antibody that comprises: a variable heavy chain region linked to a heavy chain constant domain, the heavy chain variable region comprises a complementary determining region (CDR)1 comprising the amino acid sequence set forth in SEQ ID NO: 17, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 18, a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 19, and a variable light chain region linked to a light chain constant domain, the light chain variable region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:22. 12. The composition of claim 11 , wherein the antibody is affinity matured. 13. The composition of claim 11 , wherein the variable light chain region has the amino acid sequence set forth in SEQ ID NO: 6. 14. The composition of claim 11 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO: 5 with up to one amino acid difference in a framework region. 15. The composition of claim 13 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO: 5 with up to one amino acid difference in a framework region. 16. The composition of claim 11 , further comprising a pharmaceutically acceptable carrier. 17. The composition of claim 11 , wherein the composition is in a lyophilized form. 18. The composition of claim 11 , wherein the composition is in a solution form. 19. The composition of claim 15 , wherein the composition is in a lyophilized form. 20. The composition of claim 15 , wherein the composition is in a solution form.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
- C07K16/28Primary
against receptors, cell surface antigens or cell surface determinants · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Complementarity determining region [CDR] · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12098192B2 cover?
- Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
- Who is the assignee on this patent?
- Abbvie Deutschland, Abbvie Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).